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Abstract
Background: The management of multiple sclerosis (MS) is rapidly changing by the introduction of new and more
effective disease-modifying agents. The importance of risk stratification was confirmed by results on disease
progression predicted by different risk score systems. Despite these advances, we know very little about medical
decisions under uncertainty in the management of MS. The goal of this study is to i) identify whether
overconfidence, tolerance to risk/uncertainty, herding influence medical decisions, and ii) to evaluate the frequency
of therapeutic inertia (defined as lack of treatment initiation or intensification in patients not at goals of care) and
its predisposing factors in the management of MS.
Methods/Design: This is a prospective study comprising a combination of case-vignettes and surveys and
experiments from Neuroeconomics/behavioral economics to identify cognitive distortions associated with medical
decisions and therapeutic inertia. Participants include MS fellows and MS experts from across Spain. Each participant
will receive an individual link using Qualtrics platform© that includes 20 case-vignettes, 3 surveys, and 4 behavioral
experiments. The total time for completing the study is approximately 30–35 min. Case vignettes were selected to
be representative of common clinical encounters in MS practice. Surveys and experiments include standardized test
to measure overconfidence, aversion to risk and ambiguity, herding (following colleague’s suggestions even when
not supported by the evidence), physicians’ reactions to uncertainty, and questions from the Socio-Economic Panel
Study (SOEP) related to risk preferences in different domains. By applying three different MS score criteria (modified
Rio, EMA, Prosperini’s scheme) we take into account physicians’ differences in escalating therapy when evaluating
medical decisions across case-vignettes.
Conclusions: The present study applies an innovative approach by combining tools to assess medical decisions
with experiments from Neuroeconomics that applies to common scenarios in MS care. Our results will help
advance the field by providing a better understanding on the influence of cognitive factors (e.g., overconfidence,
aversion to risk and uncertainty, herding) on medical decisions and therapeutic inertia in the management of MS
which could lead to better outcomes.
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Background
The field of multiple sclerosis (MS) has seen significant
changes over the last several years [1, 2]. Clinicians and pa-
tients welcomed the introduction of disease-modifying
therapy (DMT) for MS in the mid-1990s. Injectable agents,
all with rather similar risk–benefit profiles, dominated MS
care for over a decade. The approval of Natalizumab
marked a change with the introduction of a more effective
treatment option, but also entailed new risks associated
with modulation of the immune system (e.g., risk of pro-
gressive multifocal leukoencephalopathy - PML) [2, 3].
More recently, the introduction of oral agents and new
humanised monoclonal antibodies administered by infu-
sion have opened yet another avenue for patients and clini-
cians [4]. Currently, there are over a dozen of DMTs
available to treat MS, with varying availability around the
world. Significant heterogeneity exists in the efficacy and
risks associated with these therapies [5–7]. Therefore, clini-
cians have the challenge of tailoring treatment based on i)
disease activity level (clinical and radiological data), ii) indi-
vidual patient characteristics/preferences, iii) personal ex-
pertise/preference, in order to identify the optimal balance
between efficacy and safety Table 1 (See Additional file 1
for data on some currently available agents) [8].
Risk stratification in MS
An understanding of the risk of untreated multiple scler-
osis is crucial to make therapeutic decisions Table 2 [8]. In
addition, physicians’ preferences and beliefs in effective-
ness of treatment and drug safety profiles may influence
their decisions. Disease activity/progression can be di-
vided into physical, cognitive and radiological markers.
Examples include number of attacks per year, number of
disabling attacks, disability scales (clinical), lesion vol-
ume, GAD enhancing lesions, brain atrophy (MRI), and
cognitive decline (e.g., using SDMT, PASAT, OR MoCA
scales) [9]. Two scoring systems (Rio score and Modified
Rio score) demonstrate good predictive value for MS
progression. The Rio score includes MRI, clinical relapse
and EDSS criteria, whereas the modified Rio score in-
cludes MRI and clinical relapse criteria (Fig. 1) [10]. A
high risk profile using the modified Rio (score ≥2) in-
cludes either an MRI with more than 5 new T2 lesions
(1 point) or 1 relapse in the first year (1 point) or two
relapses within the first year of treatment (2 points) or
the combination of these criterions [11]. These scores
have been used to identify and predict response to Inter-
feron β. For example, the modified Rio score in the
PRISM trial revealed that participants who did not
responded to Interferon β had a similar probability of
disability progression as those assigned to the placebo
group. Conversely, responders to Interferon β had a
52 % reduction in disability progression compared to
placebo and non-responders (p < 0.0001). MS patients
with a modified Rio score greater than or equal to 2 had
a 65 % increased risk of disability progression (HR =
4.60; p < 0.001) [12]. A Canadian group concluded that a
change in treatment may be considered in patients with
relapsing remitting MS if there is a high level of concern
in any one domain (relapses, progression or MRI), a
medium level of concern in any two domains, or a low
level of concern in all three domains [13]. The European
Table 1 Comparative adverse events of different DMTs [7, 8]
Disease modifying agent Adverse events







Glatiramer acetate • ISRs
• Benign systemic reaction
Mitoxantrone • Cardiac toxicity
• Leukemia















Dimethyl fumarate • Flushing
• Gastrointestinal
• PML





• Autoimmune thyroid disease
ISRs injection-site reactions, LFT liver function test, PML progressive multifocal
leukoencephalopathy, ITP idiopathic thrombocytopenic purpura, BCC basal
cell carcinoma
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Medicines Agency approves escalating therapy with
Natalizumab or Fingolimod in patients who had at least
one relapse in the previous year while on Interferon β
and either ≥9 T2-hyperintense lesions on brain MRI or
≥1 contrast-enhancing lesion MRI activity alone after
the first year of treatment was associated with three- to
fivefold increased risk of relapses or disability compared
with stable patients. These recommendations have been
supported by several prospective studies [14, 15].
Selection of a first line therapy will likely depend on sev-
eral factors. Traditionally, and due to the availability of ex-
tended safety data, injectable agents may be the first
choices. Given the comparable efficacy data between the
injectable agents the selection of a therapy will be deter-
mined mostly by side effect profiles. Subjects with head-
aches, depression, and a history of liver dysfunction may
experience worsening of these comorbidities when ex-
posed to interferons. Monitoring for interferons includes
following liver function tests, complete blood counts, and
monitoring depression [8]. Given the availability of more
effective drugs, the treatment paradigm is likely to change.
However, it is expected there will be wide variability on
the timing of this paradigm shift (e.g., starting more effect-
ive therapies as first line treatment) based on patients’ and
physicians’ tolerance to risk, estimation of the clinical
course, regional funding programs, among other factors.
As a result, it is vital to identify situations for which physi-
cians take the opportunity of escalating treatment when
indicated (e.g., progression of disease determined by clin-
ical relapses, EDSS disability score and imaging data).
Therapeutic inertia: a new paradigm in MS
Therapeutic inertia is a term introduced in 2006 to de-
fine the lack of treatment initiation or intensification in
patients not at goals of care [16–19]. Some examples in-
clude failure to intensify treatment in patients with per-
sistent elevated blood pressure or blood glucose [16, 20,
21]. Reasons to explain therapeutic inertia include the
lack of training and cultural organization in the practice
at “treating to target”, competing demands and clinical
uncertainty [22, 23]. In the context of MS, therapeutic
inertia is defined lack of treatment initiation or intensifi-
cation when there is evidence of disease progression (based
on clinical and radiological data). In the present study,
Table 2 Risks of untreated relapsing MS
Treatment targets Evidence of association Long-term outcome
T2 lesion volume Increase of 0.8–l ml/year Correlates with increased relapse frequency and long term
disability outcomes.
T1 black hole conversion 40–50 % of lesions go on to form black holes Correlation with clinical measures and disability progression.
Brain atrophy 0.5–1 %/year in MS vs. <0.1 % in healthy controls Correlation with cognitive outcomes and EDSS in the long term.
Clinical relapses Annualized relapse rate in placebo arms: 0.5–1.38 Relapses associated with decreased quality of life.
Relapses associated with accrual of disability.
Earlier onset of SPMS.
Disability accrual Average change of 0.27 EDSS points/per relapse Increased likelihood of long term disability.
MRI and lesional activity associated with disability progression
Reproduced with permission from Ontaneda et al. [8]
Fig. 1 Modified with permission from Sormani et al. defining and scoring response to IFN‑β in multiple sclerosis. Nat. Rev.
Neurol. doi:10.1038/nrneurol.2013.146
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disease progression was defined according to the modified
Rio score, where patients had one or more recurrent at-
tacks and/or an MRI with 5 or more new T2 lesions while
receiving treatment with a disease- modifying agent [11].
Another more recent criterion strongly associated with risk
of relapse or disability progression was the presence of iso-
lated gadolinium-enhancing lesions [14, 15].
Medical decision making
Making decisions in medical care is a complex task involv-
ing a variety of cognitive processes [24]. Decision making is
defined as the process of examining possibilities, risks, un-
certainties, and options, comparing them, and choosing a
course of action [25, 26]. Decisions based on erroneous as-
sessments may result in incorrect patient and family expec-
tations, and potentially suboptimal advice, treatment, and
prognosis. Moreover, many decisions are made with limited
information from observational studies or clinical trials that
may not apply to particular patients. Uncertainty is one of
the most important reasons contributing to the status quo
and making proactive therapeutic decisions [17, 23, 27].
We need a better understanding on how physicians decide
about different therapeutic options under uncertainty for
patients with MS.
The problem
Despite the availability of different markers for risk
stratification in patients with MS, it is difficult for expert
clinicians to select the best strategy when the progres-
sion pattern of the disease is uncertain. MS experts and
clinicians are trained to quickly recognize patterns or
critical aspects of particular situations [28]. Some clini-
cians apply the knowledge they have acquired from pre-
vious experience, others use information available at the
time of the assessment, others use risk score tools or a
combination of the above. However, it is not known how
MS experts behave in clinical scenarios with ambiguous
outcomes (unknown probability or uncertain risk of an
outcome) or when more therapeutic options become avail-
able. In addition, we have a limited understanding about
physicians’ beliefs and preferences on the widely available
therapeutic options for the optimal management of MS.
Moreover, there is still lack of evidence-based ap-
proaches to incorporate patients’ preferences such as
medication disutility into the shared decision making
process [29]. As our understanding of MS risk continues
to be refined, how to account for the uncertain risks, ben-
efits, and preferences at the individual level is a current
challenge for the practice of personalized medicine.
The proposed solution: bringing together
advances in MS treatment and Neuroeconomics
The expected utility theory states that decision makers
choose between risky or uncertain options by comparing
their expected utility values (i.e.,: the weighted sums ob-
tained by adding the utility values of outcomes multiplied
by their respective probabilities) [30]. More importantly,
patients’ preferences and physicians’ recommendations
will change depending on the utility function of their
current health status. For example, patients at low risk of
developing MS progression may prefer to avoid ‘risky’
treatments (as they have low gains while having a risk of
developing side effects), whereas high-risk patients would
prefer the most effective treatment even if need to take
higher risks (as they have a higher chance of having a pro-
gression leading to more disability) (Fig. 2) [24, 31].
Rationale
Neuroeconomics is the science that studies the principles
of how we make decisions [30, 32]. The neuroscience of
decision making is based on behavioral economic concepts
and mathematical approaches, such as game theory, to pre-
dict and model how people make their own choices [33].
The application of principles from Neuroeconomics
(decision neuroscience) will facilitate the recognition of
physicians’ therapeutic preferences and beliefs about
DMT for MS in the real world [34] (Fig. 3). Given the
greater availability of treatment options, MS treatment
will likely become more challenging. It requires a fine
balance between the modest benefits of the less expen-
sive, safer, and traditional DMTs versus new agents, usu-
ally more costly with potential harmful side effects. The
so called ‘intermediate agents’ (e.g., Fingolimod) may
have a ‘decoy effect’ (Phenomenon whereby consumers
tend to have a specific change in preference between
two options when also presented with a third -less pref-
erable- option becomes available) [35, 36].
There is limited evidence of the application of the ex-
pected utility theory to clinical scenarios from the physi-
cians’ perspective. A better understanding of physicians’
beliefs and preferences under uncertainty would likely
improve the quality of care, patients’ satisfaction, and
likely improve clinical outcomes by increasing awareness
on the therapeutic inertia in MS.
Objectives
1) To evaluate tolerance to risk and ambiguity among
MS experts under situations of uncertainty.
2) To assess the prevalence of ‘therapeutic inertia’.
3) To determine the influence of tolerance to risk/
ambiguity, overconfidence and herding on medical
decisions.
Research questions
1) How MS experts’ perceptions of risk and tolerance
to ambiguity influence their recommendations?
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2) What is the prevalence of therapeutic inertia among
physicians with expertise in MS?
3) What is the impact of tolerance to risk and
ambiguity, overconfidence and herding on
therapeutic decisions?
Methods
We are proposing a prospective web-based study com-
prising 20 MS case-vignettes, 3 standardized surveys,
and 4 behavioral experiments (see Additional file 1).
MS case-scenarios were derived from the most
common situations in clinical practice as identified by
experts in the field. Surveys include three standard-
ized questions related to aversion to risk from The
German Socio-Economic Panel (SOEP) study. The
SOEP is a longitudinal study of private households
that include household composition, occupational
biographies, employment, earnings, health and satis-
faction indicators [37, 38]. The English version is
available online [39].
Fig. 3 Framework
Fig. 2 Illustrative comparison of risk aversion changes as a function of wealth and health
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Based on our previous work including a systematic litera-
ture review of studies evaluating cognitive biases or distor-
tions in the medical field, we selected tolerance to risk and
ambiguity, overconfidence, herding, and decisions about
someone else [40]. We used the physician’s reaction to un-
certainty test to assess tolerance to risk or ambiguity in pa-
tient care [41]. This questionnaire comprised an initial pool
of 61 items [41]. Factor analysis of the 428 respondents re-
vealed a high accuracy (Cronbach's alpha = 0.90). The short
version of this questionnaire includes five questions [42].
Behavioral experiments were designed to elicit risk and
ambiguity aversion in the health and financial domains
[43, 44], herding (decisions influenced by other colleagues)
[45], decisions about someone else vs. own, and overconfi-
dence (perception that own judgments are more accurate
or in the top 50 % of the studied population) [46].
Participants
Neurologists actively involved in the care of patients
with MS from across Spain will be invited to participate
in our study. Invitations are facilitated by the Spanish
Society of Neurology (Sociedad Española de Neurologia).
We use Qualtrics platform for the design and implemen-
tation of our study. It is expected physicians will be able
to complete the study within 30 min.
Participating physicians will receive fair market compen-
sation for the time involved in completing the survey.
Outcome measures
The primary outcome of the study is the proportion of
participants who exhibit aversion to ambiguity and thera-
peutic inertia [19, 43]. Ambiguity aversion is defined as is
a preference for known risks over unknown risks [43].
This can be elicited through the experiments #16 and #17
in the health and financial domains (Additional file 1).
Therapeutic inertia will be assessed based on the se-
lected treatment options in case-scenarios with recur-
rent relapses, appearance of new brain lesions in follow
up MRI’s while taking a disease modifying agent over a
specified period. Secondary outcome measures include
the association between risk aversion, overconfidence,
and herding with therapeutic decisions and the assess-
ment of therapeutic inertia using different criteria.
Sample size calculation
Based on the results of pilot studies evaluating other
medical conditions (e.g., atrial fibrillation) and our sys-
tematic review on the frequency of cognitive distortions
affecting physicians [40], we require a sample size of 120
physicians (60 per group) (Table 3) to reach 90 % power
to detect a conservative 20 % absolute difference in
therapeutic inertia between participants exposed and not
exposed to cognitive distortions.
Feasibility
the study interventions are simple and doable. The protocol
includes clinical scenarios commonly observed in clinical
practice. According to the Spanish Neurological Society
(Sociedad Española de Neurología-SEN), there are over
1600 neurologists, 13 specialized MS centers comprising
approximately 200 specialists in the field in Spain. Assum-
ing a low response rate of 50 %, the completion of our study
is feasible considering the required sample size to reach a
power of 90 % with an alpha of 5 %.
Analytical plan
To address objective 1, we will characterize participants’
risk and ambiguity aversion as identified by the corre-
sponding experiments (Additional file 1, behavioral bat-
tery questions (Q) #1 to 4.
To address objective 2, we evaluate therapeutic inertia
(TI) as elicited by 10 case-vignettes. We will created a TI
score representing the number of cases that participants
did not escalate treatment (numerator) over 10 (denom-
inator) multiplied by 100. The diversity of case-scenarios
will also allow the analysis of therapeutic inertia using
different criteria (e.g., modified Rio score, European
Medicines Agency, isolated GAD-enhanced lesions).
To address objective 3, we will complete a univariate
and multivariable analysis to determine the influence of
risk aversion, tolerance to ambiguity, overconfidence and
herding on therapeutic decisions and TI score.
Chi squared tests will be used to compare categorical
variables; t-test or Kruskal-Wallis tests will be used to
compare mean and median differences for continuous
variables. The primary analysis will evaluate the associ-
ation between physicians’ responses in the behavioral
component of the survey with responses in the case-
scenarios. A multivariable analysis will be completed to
determine the association between physicians’ character-
istics with the primary outcome of interest. Adjustment
includes the following variables: age, sex, years of experi-
ence, expertise, volume of MS patients seen per week,
and practice setting (academic vs. community). All tests
were 2-tailed, and p-values <0.05 will be considered
significant.
Knowledge translation strategies
We plan to take a multifaceted approach to knowledge
translation, targeting the following audiences for com-
munication: 1) Neurologist, 2) the clinical academic
Table 3 Sample size calculation
Powera 90 % 85 % 80 %
N (per group) 60 53 46
aThe power was calculated to detect a 20 % absolute difference between
groups (40 % vs 20 %) with an alpha of 5 % (two-sided) for all of the
calculations in the table
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community, 3) the media, 4) policy-makers, and 5) MS
patients and their families. We expect to generate high
impact publications and media interest to inform the
public and influence MS care programs. This work is
also expected to increase awareness about therapeutic
inertia among MS experts and to contribute toward new
guidelines for the management of MS. We are working
with key stakeholders to discuss the most effective dis-
semination strategy and target the key messages for all
audiences.
Discussion
Patients and physicians caring for patients with MS are
confronted with important uncertainties concerning the
diagnosis, prognosis, disease course, and disease-
modifying therapies. In the recent years, new therapeutic
alternatives became available for management of MS [5,
47]. These advances were achieved by targeting different
pathophysiological mechanisms, producing more effect-
ive DMTs, but accompanied by either higher risk of in-
fections, or more serious side effects [48]. As a result,
MS experts have an expanded therapeutic arsenal com-
pared to a decade ago. Decisions are not merely about
the selection of an injectable interferon or Glatiramer
(given daily or every other day) usually accompanied by
skin reactions or flu-like symptoms, but rather the indi-
vidual selection of the most appropriate DMT (e.g., dose,
administration type, efficacy and safety profile) according
to disease severity, patient’s clinical status and prefer-
ence. Consequently, more effective agents are now more
accessible for MS patients who failed traditional DMT
[5, 49].
Interestingly, physicians have limited education in both
risk management and in formal training in decision
making [50, 51].
We are proposing a novel approach in expanding re-
search of MS care by combining case-vignettes with the
assessment of cognitive distortions through experiments
in Neuroeconomics (Decision Neuroscience). The appli-
cation of Neuroeconomics’ principles may help over-
come those barriers by identifying and increasing
awareness about cognitive distortions (e.g., overconfi-
dence, tolerance to risk and ambiguity, etc.) that may
lead to suboptimal decisions (e.g., therapeutic inertia)
[18, 25, 52].
This study will provide evidence about: i) how MS ex-
perts make decisions under uncertainty, ii) how MS ex-
perts would change their preferences based on their
tolerance to risk and ambiguity, iii) the prevalence of
therapeutic inertia based on different criteria for escalat-
ing therapy (modified Rio, European Medicines Agency),
and iv) the influence of cognitive distortions on thera-
peutic inertia.
DIScUTIR MS is designed as a pilot study to deter-
mine the feasibility of assessing tolerance to risk and
ambiguity, therapeutic inertia, and associated factors
among practicing physicians with expertise in MS.
The results of our study will also facilitate crucial in-
formation to understand current MS care practices and
how physicians’ preferences (e.g., risk aversion) have a
global impact on medical and daily life decisions.
Some limitations need to be acknowledged. First,
the small sample size of MS experts from a single
country (Spain) would limit the generalizability of the
results. However, DIScUTIR MS is designed as a pilot
study to determine the feasibility of a larger world-
wide study. Second, the concept and definition of
therapeutic inertia applied to MS care is not widely
disseminated. Some colleagues may also argue about
the absence of an accepted definition of therapeutic
inertia in MS care. However, we used a widely accept-
able definition of TI supported by studies showing
health care improvements in the management of key
and widely prevalent conditions (i.e.,: blood pressure
and diabetes).
Despite the aforementioned limitations, our study
will increase physicians’ awareness of crucial situa-
tions under uncertainty in the management of MS.
The results of DIScUTIR MS will provide a starting
point to ignite discussions about a widely accepted
definition of therapeutic inertia in MS care. This is
relevant considering the lack of MS guidelines con-
cerning clinical scenarios under uncertainty or pro-
gression of disease [53, 54].
The identification of clinical or radiological progres-
sion in MS should at least set the time of ‘thera-
peutic momentum’ to consider escalating treatment,
especially when cost-effective options are available. In
this setting, physicians may want to take that oppor-
tunity to discuss risk-benefit scenarios in a way simi-
lar to how financial advisors assess their clients’
preferences and risk tolerance when advising about a
variety of investment portfolios. An open discussion
in risky situations following the appropriate documen-
tation of disease progression would ameliorate the
therapeutic inertia and may lead to more optimal de-
cisions in the care of patients with MS.
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